BindingDB logo
myBDB logout

223 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27839919 192 Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples.EBI University of Kansas
27132867 154 Structure-guided development of dual▀2 adrenergic/dopamine D2 receptor agonists.EBI Friedrich-Alexander University
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26704965 229 Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.EBI University of Illinois at Chicago
26709102 142 Discovery of Vibegron: A Potent and Selective▀3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.EBI Merck Research Laboratories
26471092 23 Molecular hybridization yields triazole bronchodilators for the treatment of COPD.EBI Pfizer
26125514 40 Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human▀3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.EBI Asahi Kasei Pharma Corporation
25695425 62 Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.EBI City University of New York
25629394 52 Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist..EBI Theravance Biopharma, Inc.
25065493 92 The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting▀2-adrenoceptor agonist.EBI Novartis Institutes for BioMedical Research
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
25241924 47 The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.EBI Novartis Institutes for BioMedical Research
24835980 98 Discovery of TD-4306, a long-acting▀2-agonist for the treatment of asthma and COPD.EBI Theravance, Inc.
24878222 50 Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.EBI Pfizer Inc.
24813741 110 Multivalent design of long-acting▀(2)-adrenoceptor agonists incorporating biarylamines.EBI Theravance, Inc.
16640337 47 Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.EBI GlaxoSmithKline
2870189 11 Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.EBI TBA
23614528 121 Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists.EBI University of Nottingham
21870877 119 Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors.EBI University of Nottingham
11806709 63 Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.EBI GlaxoSmithKline
2993621 34 Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.EBI TBA
22932315 28 An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol.EBI Novartis Institutes for BioMedical Research
22079756 219 From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
22178551 46 A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD.EBI Theravance, Inc.
21925889 48 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group.EBI GlaxoSmithKline Medicines Research Centre
21696967 51 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings.EBI GlaxoSmithKline Medicines Research Centre
21723724 91 Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
21652207 17 Design driven HtL: The discovery and synthesis of new high efficacyß2-agonists.EBI AstraZeneca
20462258 50 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.EBI GlaxoSmithKline Medicines Research Centre
19317397 62 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.EBI GlaxoSmithKline Medicines Research Centre
19146417 70 The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.EBI GlaxoSmithKline Pharmaceuticals
18433113 124 Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.EBI GlaxoSmithKline
11311067 38 Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.EBI Kissei Pharmaceutical Company Ltd.
9548813 53 The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.EBI SmithKline Beecham Pharmaceuticals
11454468 35 Discovery and SAR of org 24598-a selective glycine uptake inhibitor.EBI Organon Research and Development Group
21486038 177 Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.EBI H. Lundbeck A/S
23641311 38 From a4▀2 Nicotinic Ligands to the Discovery of s1 Receptor Ligands: Pharmacophore Analysis and Rational Design.EBI TBA
22563707 27 A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design.EBI Radboud University Nijmegen Medical Centre
22313227 78 Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.EBI National Institute of Mental Health
24900353 6 Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.EBI TBA
21207959 69 Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.EBI National Institute of Mental Health
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20684563 176 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.EBI H. Lundbeck A/S
20181479 177 Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.EBI Merck Research Laboratories
19963380 38 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.EBI Hunter College and the Graduate Center of the City University of New York
19821575 47 Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.EBI GlaxoSmithKline
19608416 29 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.EBI Astellas Pharma Inc
19168263 14 Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.EBI Instituto Polit£cnico Nacional
19581100 162 Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
19232786 72 Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
18651730 123 Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.EBI Astellas Pharma Inc
18307290 97 Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.EBI Astellas Pharma Inc.
17897826 18 The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.EBI Pfizer Global Research and Development
17845020 44 Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.EBI Universit£ degli Studi di Torino
17498952 4 The discovery of long acting beta2-adrenoreceptor agonists.EBI Pfizer Global Research and Development
16451077 86 Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.EBI Pfizer Inc.
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
15603933 28 Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.EBI Fujisawa Pharmaceutical Co. Ltd
15324892 9 Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.EBI Novartis Horsham Research Centre
12502364 17 Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.EBI Kissei Pharmaceutical Company Ltd.
12213075 70 Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).EBI Purdue University
11311069 64 (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.EBI Wyeth-Ayerst Research
8691440 22 Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.EBI University of Pennsylvania
7658429 31 (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).EBI Abbott Laboratories
8254623 20 Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.EBI National Institute of Diabetes and Digestive and Kidney Diseases
8230093 21 Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.EBI Universit£ di Pisa
1313109 20 Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.EBI Universit£ di Pisa
6126588 34 Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.EBI TBA
15203136 39 (+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.EBI Virginia Commonwealth University
22182578 13 Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the humanß2-adrenoceptor.EBI Instituto Polit£cnico Nacional
21863888 9 Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease.EBI Pfizer Inc.
21783363 10 Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.EBI University of Toronto
21591752 41 Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.EBI Soochow University College of Pharmaceutical Sciences
20036561 39 Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.EBI Medical University of Lublin
21615150 14 Progress in structure based drug design for G protein-coupled receptors.EBI Heptares Therapeutics Limited
21075627 26 Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.EBI Pfizer Inc.
21353541 25 Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.EBI Merck Research Laboratories
21310610 63 Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.EBI Theravance, Inc.
24900301 24 Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid HormoneEBI TBA
20833036 221 Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization.EBI 4SC AG
20812727 157 Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.EBI National Institute of Mental Health
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20804199 23 Inhalation by design: novel ultra-long-actingß(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.EBI Pfizer Inc.
20655218 72 A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.EBI Novartis Institutes for BioMedical Research
20620058 41 Smoothened antagonists for hair inhibition.EBI Pfizer Inc.
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20434333 111 A vHTS approach for the identification of beta-adrenoceptor ligands.EBI 4SC AG
20402514 34 The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.EBI Novartis Institutes for Biomedical Research
20384344 42 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.EBI Meiji Seika Kaisha, Ltd.
20096576 41 Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19857969 6 Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines.EBI National Institute of Diabetes and Digestive and Kidney Diseases
19646882 72 Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.EBI University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and the Informatics Institute of UMDNJ
19646865 45 Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.EBI Pfizer Global Research and Development
19643607 26 Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19875286 44 Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.EBI Boehringer Ingelheim Pharma GmbH& Co KG
 38 Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivityEBI TBA
 26 BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonistEBI TBA
19492813 56 Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.EBI GlaxoSmithKline
19366244 138 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.EBI Astellas Pharma Inc.
19362005 74 Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc
19081260 10 Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.EBI Central Drug Research Institute
18829308 5 Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.EBI Lundbeck Research USA, Inc.
18656910 2 Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol.EBI Centre for Addiction and Mental Health
18573659 47 Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.EBI GlaxoSmithKline
18553954 126 Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.EBI Astellas Pharma Inc.
18507369 85 Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.EBI Theravance, Inc.
18180157 10 Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.EBI St. Jude Children's Research Hospital
17911024 37 Potent oxindole based human beta3 adrenergic receptor agonists.EBI Lilly Research Laboratories
17804228 44 Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.EBI Lilly Research Laboratories
17632003 55 Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.EBI Pfizer Global Research and Development
17571866 49 Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.EBI National Institute of Mental Health
17533126 78 Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17524641 69 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI GlaxoSmithKline
17506540 52 Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.EBI Medical University of Lublin
17303428 22 Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.EBI Università degli Studi di Milano
16931005 21 Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.EBI Lilly Research Laboratories
16392798 46 Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.EBI Columbia University College of Physicians and Surgeons
15686912 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.EBI Dainippon Pharmaceutical Co., Ltd
15546708 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.EBI Dainippon Pharmaceutical Co., Ltd
15546707 60 Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.EBI Dainippon Pharmaceutical Co., Ltd
14643338 124 Binding of beta-carbolines at 5-HT(2) serotonin receptors.EBI Virginia Commonwealth University
12798332 35 Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.EBI Wyeth Research
12657269 52 Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines.EBI Dainippon Pharmaceutical Co., Ltd.
12361399 17 Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.EBI Universita di Camerino
12270184 34 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines.EBI Wyeth Research
12270183 45 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines.EBI Wyeth Research
11327605 27 New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11277513 25 2,4-Thiazolidinediones as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11212115 72 Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.EBI Merck Research Laboratories
11055339 59 Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
11052788 33 Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.EBI Merck Research Laboratories
10999482 52 Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.EBI Merck Research Laboratories
10987429 69 Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.EBI Merck Research Laboratories
10915043 69 Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
10888325 90 Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.EBI Merck Research Laboratories
10888324 48 Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.EBI Merck Research Laboratories
10406657 91 Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.EBI Merck Research Laboratories
10360736 2 S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp.EBI Kirin Brewery Co., Ltd.
10340609 15 L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.EBI Merck Research Laboratories
10201842 69 Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.EBI Merck Research Laboratories
10201841 47 Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.EBI Merck Research Laboratories
9873681 65 3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.EBI Merck Research Laboratories
9873496 80 3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.EBI Merck Research Laboratories
9871717 72 Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.EBI Merck Research Laboratories
9871716 94 Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.EBI Merck Research Laboratories
9379432 36 Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prEBI Abbott Laboratories
7910217 36 The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.EBI Universitá di Pisa
2892936 10 Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.EBI Warner-Lambert Company
2875184 11 (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.EBI TBA
1967313 21 Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.EBI University of California
1648138 33 Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.EBI Universitá di Catania
1354264 16 Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.EBI American Cyanamid Company
19337725 43 Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.BDB Case Western Reserve University
17221184 55 Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.BDB Columbia University
16915381 31 WAY-100635 is a potent dopamine D4 receptor agonist.BDB Purdue University
16352709 44 Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.BDB McGill University
16051698 5 Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.BDB Institute of Cell Signaling
15999145 62 Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.BDB Case Western Reserve University
21926995 79 Ligand discovery from a dopamine D3 receptor homology model and crystal structure.BDB University of California San Francisco
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
14730417 62 Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.BDB Universität Würzburg
12784105 53 Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.BDB Case Western Reserve University
12761331 97 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.BDB Case Western Reserve University
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
12649361 779 L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.BDB Case Western Reserve University
12431845 84 Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.BDB Lilly Research Laboratories
12388666 301 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.BDB Institut de Recherches Servier
12192085 52 Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.BDB Case Western Reserve University
12110997 380 In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.BDB Westfälische Wilhelms-Universitä Muenster,
11750183 29 Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.BDB Novartis Pharma
11750180 139 Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.BDB Lilly Research Laboratories
11512051 80 The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.BDB Case Western Reserve University
11438309 51 The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.BDB Janssen Research Foundation
11356907 15 Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.BDB Institut de Recherches Servier
11303056 2 Pharmacological characterization of KUR-1246, a selective uterine relaxant.BDB Kissei Pharmaceutical Co., Ltd.
11082457 63 S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.BDB Centre de Recherches de Croissy
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
10379421 134 Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.BDB TBA
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche
9395253 17 Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.BDB Eli Lilly and Co.
9336327 37 The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.BDB Preclinical R & D, Astra Arcus AB
9225287 174 RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.BDB Roche Bioscience
9144661 24 BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats.BDB SmithKline Beecham Pharmaceuticals
8996185 121 Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.BDB Synthélabo Recherche
8935801 586 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.BDB Janssen Research Foundation
8887981 72 A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.BDB Abbott Laboratories
8822531 111 Radioreceptor binding profile of the atypical antipsychotic olanzapine.BDB Lilly Research Laboratories
8788493 64 Novel discriminatory ligands for 5-HT2B receptors.BDB SmithKline Beecham Pharmaceuticals
8730737 23 Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.BDB SmithKline Beecham Pharmaceuticals
8584042 40 BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.BDB Boehringer Ingelheim Italia
8564266 77 Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.BDB Vrije Universiteit
8564196 35 Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.BDB Syntex Discovery Research
8386236 11 In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.BDB Whitby Research, Inc.
8093723 20 Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.BDB Dainippon Pharmaceutical Co., Ltd.
7921604 16 The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon.BDB SmithKline Beecham Pharmaceuticals
7915318 120 Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism.BDB Ohio State University
7910212 34 Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.BDB Yamanouchi Pharmaceutical Co. Ltd.
7523657 14 Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.BDB Eli Lilly and Company
7518514 46 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.BDB Abbott Laboratories
3790168 23 Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.BDB Wyeth Laboratories, Inc.
2869639 166 Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.BDB Astra Läkemedel AB
2583244 35 Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.BDB Virginia Commonwealth University
2537663 10 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.BDB Stanford University
1968985 56 Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.BDB Niigata College of Pharmacy
1352553 38 Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.BDB University of North Carolina
8699 51 Beta adrenergic receptor binding in membrane preparations from mammalian brain.BDB TBA
19245211 9 Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.BDB Intervet Innovation GmbH
15655528 75 The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.BDB University of Nottingham
18783211 14 Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.BDB Monash University